Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier

Naji J. Riachi, W. Dalton Dietrich, Sami I. Harik

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Unlike primates, rats are resistant to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, but direct infusion of MPTP into rat substantia nigra causes specific destruction of dopaminergic neurons. We now demonstrate that rats are resistant to MPTP neurotoxicity even when MPTP is injected directly into the brain circulation. Injection of 1-3.5 mg of MPTP into the internal carotid artery of Wistar rats causes no behavioral or motor abnormalities and small, but significant, dopamine loss in the ipsilateral striatum. MPTP caused no changes in the levels of norepinephrine or serotonin in the cerebral cortex. Higher doses of intracarotid MPTP were lethal. Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion. The high uptake and retention of MPTP by rat brain, yet its failure to cause major dopaminergic toxicity suggest that MPTP is rapidly metabolized in brain capillaries to 1-methyl-4-phenylpyridinium (MPP+) and other polar metabolites that have difficulty in traversing the blood-brain barrier. Sequestration of MPTP metabolites in brain capillary endothelial cells could result in their dysfunction. However, we found no defects in the ability of the blood-brain barrier to prevent the entry of vascular aminoisobutyric acid or horseradish peroxidase into brain in spite of morphologic evidence of endothelial changes and astrocytic swelling after intracarotid MPTP injections. Our results provide further evidence that the rat's resistance to systemic MPTP neurotoxicity is probably due to its unique blood-brain barrier properties.

Original languageEnglish
Pages (from-to)6-14
Number of pages9
JournalBrain Research
Volume533
Issue number1
DOIs
StatePublished - Nov 12 1990

Fingerprint

Blood-Brain Barrier
Brain
Dopamine
4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenylpyridinium
Aminoisobutyric Acids
Pargyline
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Injections
Monoamine Oxidase Inhibitors
Dopaminergic Neurons
Internal Carotid Artery
Substantia Nigra
Horseradish Peroxidase
Cerebral Cortex
Primates
Blood Vessels
Wistar Rats
Serotonin
Norepinephrine

Keywords

  • Blood-brain barrier
  • Dopaminergic neurotoxicity
  • Monoamine oxidase
  • MPP
  • MPTP
  • Rat resistance to MPTP toxicity

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. / Riachi, Naji J.; Dalton Dietrich, W.; Harik, Sami I.

In: Brain Research, Vol. 533, No. 1, 12.11.1990, p. 6-14.

Research output: Contribution to journalArticle

@article{e3ca2655148047b6a9177d895f23fcbf,
title = "Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier",
abstract = "Unlike primates, rats are resistant to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, but direct infusion of MPTP into rat substantia nigra causes specific destruction of dopaminergic neurons. We now demonstrate that rats are resistant to MPTP neurotoxicity even when MPTP is injected directly into the brain circulation. Injection of 1-3.5 mg of MPTP into the internal carotid artery of Wistar rats causes no behavioral or motor abnormalities and small, but significant, dopamine loss in the ipsilateral striatum. MPTP caused no changes in the levels of norepinephrine or serotonin in the cerebral cortex. Higher doses of intracarotid MPTP were lethal. Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion. The high uptake and retention of MPTP by rat brain, yet its failure to cause major dopaminergic toxicity suggest that MPTP is rapidly metabolized in brain capillaries to 1-methyl-4-phenylpyridinium (MPP+) and other polar metabolites that have difficulty in traversing the blood-brain barrier. Sequestration of MPTP metabolites in brain capillary endothelial cells could result in their dysfunction. However, we found no defects in the ability of the blood-brain barrier to prevent the entry of vascular aminoisobutyric acid or horseradish peroxidase into brain in spite of morphologic evidence of endothelial changes and astrocytic swelling after intracarotid MPTP injections. Our results provide further evidence that the rat's resistance to systemic MPTP neurotoxicity is probably due to its unique blood-brain barrier properties.",
keywords = "Blood-brain barrier, Dopaminergic neurotoxicity, Monoamine oxidase, MPP, MPTP, Rat resistance to MPTP toxicity",
author = "Riachi, {Naji J.} and {Dalton Dietrich}, W. and Harik, {Sami I.}",
year = "1990",
month = "11",
day = "12",
doi = "10.1016/0006-8993(90)91788-I",
language = "English",
volume = "533",
pages = "6--14",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier

AU - Riachi, Naji J.

AU - Dalton Dietrich, W.

AU - Harik, Sami I.

PY - 1990/11/12

Y1 - 1990/11/12

N2 - Unlike primates, rats are resistant to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, but direct infusion of MPTP into rat substantia nigra causes specific destruction of dopaminergic neurons. We now demonstrate that rats are resistant to MPTP neurotoxicity even when MPTP is injected directly into the brain circulation. Injection of 1-3.5 mg of MPTP into the internal carotid artery of Wistar rats causes no behavioral or motor abnormalities and small, but significant, dopamine loss in the ipsilateral striatum. MPTP caused no changes in the levels of norepinephrine or serotonin in the cerebral cortex. Higher doses of intracarotid MPTP were lethal. Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion. The high uptake and retention of MPTP by rat brain, yet its failure to cause major dopaminergic toxicity suggest that MPTP is rapidly metabolized in brain capillaries to 1-methyl-4-phenylpyridinium (MPP+) and other polar metabolites that have difficulty in traversing the blood-brain barrier. Sequestration of MPTP metabolites in brain capillary endothelial cells could result in their dysfunction. However, we found no defects in the ability of the blood-brain barrier to prevent the entry of vascular aminoisobutyric acid or horseradish peroxidase into brain in spite of morphologic evidence of endothelial changes and astrocytic swelling after intracarotid MPTP injections. Our results provide further evidence that the rat's resistance to systemic MPTP neurotoxicity is probably due to its unique blood-brain barrier properties.

AB - Unlike primates, rats are resistant to systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, but direct infusion of MPTP into rat substantia nigra causes specific destruction of dopaminergic neurons. We now demonstrate that rats are resistant to MPTP neurotoxicity even when MPTP is injected directly into the brain circulation. Injection of 1-3.5 mg of MPTP into the internal carotid artery of Wistar rats causes no behavioral or motor abnormalities and small, but significant, dopamine loss in the ipsilateral striatum. MPTP caused no changes in the levels of norepinephrine or serotonin in the cerebral cortex. Higher doses of intracarotid MPTP were lethal. Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion. The high uptake and retention of MPTP by rat brain, yet its failure to cause major dopaminergic toxicity suggest that MPTP is rapidly metabolized in brain capillaries to 1-methyl-4-phenylpyridinium (MPP+) and other polar metabolites that have difficulty in traversing the blood-brain barrier. Sequestration of MPTP metabolites in brain capillary endothelial cells could result in their dysfunction. However, we found no defects in the ability of the blood-brain barrier to prevent the entry of vascular aminoisobutyric acid or horseradish peroxidase into brain in spite of morphologic evidence of endothelial changes and astrocytic swelling after intracarotid MPTP injections. Our results provide further evidence that the rat's resistance to systemic MPTP neurotoxicity is probably due to its unique blood-brain barrier properties.

KW - Blood-brain barrier

KW - Dopaminergic neurotoxicity

KW - Monoamine oxidase

KW - MPP

KW - MPTP

KW - Rat resistance to MPTP toxicity

UR - http://www.scopus.com/inward/record.url?scp=0025162982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025162982&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(90)91788-I

DO - 10.1016/0006-8993(90)91788-I

M3 - Article

VL - 533

SP - 6

EP - 14

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -